While the GBM definition change has board denizens cheering the improved real GBM statistics for this trial, doesn't it further clusterF the trial in general. I'm worried asking the FDA to compare to historical SOC was a big ask for FDA, now what exactly are we expecting them to do. Remove these newly classified nonGBM participants from the statistical analysis. This is screaming trial danger for me despite the beneficial knowledge improvement for GBM patients and I suppose if you're the proneural etc(bad news). One more thing. I thought there was a situation where non mes became mes upon recurrent and also temodor treatment was turning patients into mes.
Please correct and comment on my conjectures. I realize my conjectures are akin to listening to someone butcher a second language but you know what they are trying to say.
Market Data 
Markets 
AI
